Haroon Rashid, MD
Nephrology · Summerfield, FLNPI 1629006499
Payments from drug & device makers
Across 107 payments — averaging $568.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$57K
- Altathera Pharmaceuticals LLC$1K
- Amgen$737
- Mallinckrodt Hospital Products Inc.$480
- AstraZeneca$249
- Calliditas Therapeutics US Inc.$179
- plus $975 from 24 others
Across 1 payment — averaging $249.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$249
What the payments were for
- Speaking & faculty fees$1,00028%
- Food & beverage$2,28963%
- Education$3319%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 1 | $57,201 |
| Altathera Pharmaceuticals LLC | 1 | $1,000 |
| Amgen(2 entities) | 34 | $737 |
| Mallinckrodt Hospital Products Inc. | 17 | $480 |
| AstraZeneca | 9 | $249 |
| Calliditas Therapeutics US Inc. | 9 | $179 |
| Boehringer Ingelheim | 2 | $139 |
| Dova Pharmaceuticals | 1 | $109 |
| Paratek Pharmaceuticals, Inc. | 4 | $72 |
| Merck | 3 | $61 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $55 |
| Bayer | 2 | $43 |
| Gilead | 2 | $41 |
| Johnson & Johnson(2 entities) | 2 | $36 |
| Biocryst US Sales Co., LLC | 1 | $35 |
| Pfizer | 1 | $34 |
| Philips North America LLC | 1 | $33 |
| Scpharmaceuticals Inc. | 1 | $30 |
| Novartis | 1 | $29 |
| Eisai Inc. | 1 | $28 |
| Novo Nordisk | 1 | $26 |
| Lundbeck LLC | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Sanofi | 1 | $20 |
| GSK | 1 | $20 |
| Mayne Pharma Commercial LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Cumberland Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sotalol Hydrochloride$1,000
- JARDIANCE$125
- KRYSTEXXA$115
- DOPTELET$109
How this compares
$60,821 in reported general payments places this provider in the 85th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 61 | $59,010 |
| JardianceEmpagliflozin | 71 | $49,649 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $17,775 |
| Sevelamer Carbonate | 41 | $5,824 |
| SpsSodium Polystyrene Sulfon/Sorb | 12 | $5,116 |
| Allopurinol | 96 | $1,964 |
| Bumetanide | 27 | $1,693 |
| Hydralazine Hcl | 74 | $1,481 |
| Sodium Polystyrene Sulfonate | 14 | $1,431 |
| Calcium Acetate | 22 | $1,210 |
| Potassium Chloride | 56 | $1,071 |
| Calcitriol | 65 | $710 |
| Nifedipine ErNifedipine | 14 | $543 |
| Amlodipine Besylate | 51 | $459 |
| Lisinopril | 36 | $271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $249 | $76,78581 claims |
| Boehringer IngelheimJardiance | $139 | $49,64971 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 756 nephrology providers in Florida.
Other nephrology in Summerfield
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
- Jorge PosadaCoral Gables$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.